

INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT No.
012712-432APPLICATION No.
UnassignedAPPLICANT
Darrell R. ANDERSON et al.FILING DATE
August 29, 1997GROUP
Unassigned
 61001 U.S. PTO
0907608
08/29/97

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
DBS	5,500,362	3/19/96	Robinson et al.	435	7.23	3/5/91

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
(B)	0/274,394	3/88	EPO	-	-		
(B)	0451216B1	10/16/91	EPO	-	-		
(B)	0682040A1	11/15/95	EPO	-	-		
(B)	W088/04936	07/14/88	WIPO WO	-	-		
(B)	EP 173 494	05/05/86	EPO	-	-		
(B)	EP 125 023	11/14/84	EPO	-	-		
(B)	W092/07466	05/14/92	WIPO WO	-	-		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

(B)	Alvin Y. Liu et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 With Potent FC-Dependent Biologic Activity", <i>Vol. 139</i> , no. 10, 15 November 1987, 3521.
(B)	Netherlands Cancer Institute Amsterdam Annual Report 1993; A. Hekman et al., "Immunotherapy"; pages 47-48.
(B)	Journal of Cellular Biochemistry, Mitchell Reff et al., "Depletion of B Cells in Vivo By A Chimeric Mouse Human Monoclonal Antibody To CD20", vol. 17, 29 March 1993.
(B)	Sally J. DeNARDO et al., "The Biologic Window for Chimeric 1.6 Radioimmunotherapy", <i>Cancer Supplement</i> , Vol. 73, No. 3, pp 1023-1032, February 1, 1994.
(B)	Mitchell E. REFF, "Depletion of B Cells in Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20", <i>Blood</i> , Vol. 83, No. 2, pp 435-445, January 15, 1994.
(B)	<i>Genetic Engineering News</i> , "Developing Chimeric Monoclonals", Vol. 5, No. 3, March 1985.
(B)	"Antibody Shows promise to treating B Cell Lymphoma" from <i>Cope - Working in Oncology</i> , March/April 1994.
(B)	Anderson, D.R., <i>The Second Annual IBC International Conference on Antibody Engineering</i> , Dec. 16-18, 1991.
(B)	Press, O.W. 69/2, <i>Blood</i> 584 (1987)
(B)	Liu, A.-Y. 13910 <i>J. Immunol.</i> 3521 (1987)
(B)	Robinson, R.R. 2 <i>Hum. Antibod. Hybrid.</i> 84 (1991)
EXAMINER	DATE CONSIDERED 10/23/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT No.
012712-432APPLICATION No.
UnassignedAPPLICANT
Darrell R. ANDERSON et al.FILING DATE
August 29, 1997GROUP
Unassign d

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

12/5	Morrison, S.L. 81 <i>PNAS</i> 6851 (1984)
12/5	Boulianne, G.L. 312 <i>Nature</i> 643 (1984)
12/5	Neubeiger, M.D. 314 <i>Nature</i> 268 (1985)
12/5	Tan, L.K. 135 <i>J. Immunol.</i> 8564 (1985)
	Sun, L.K. 5/1 <i>Hybridoma</i> 517 (1986)
	Sahagan, B.G. 137 <i>J. Immunol.</i> 1066 (1986)
	Munro, A. 312 <i>Nature</i> 597 (1984)
	Marx 229 <i>Science</i> 455 (1985)
	Morrison 229 <i>Science</i> 1202 (1985)
	Grossbard, M.L. 80/4 <i>Blood</i> 863 (1992)
	Clark, E. 82 <i>PNAS</i> 1766 (1985)
	Robertson, M.J. 79/9 <i>Blood</i> 2229 (1992)
	Nadler, L.M. <i>The Lancet</i> 427 (8/25/84)
	Golay, J.T. 135/6 <i>J. Immunol.</i> 3795 (1985)
	Greenberger, J.S. 45 <i>Can. Res.</i> 758 (1985)
	Nadler, L.M. 40 <i>Can. Res.</i> 3147 (1980)
	Tedder, T.F. 1352 <i>J. Immunol.</i> 973 (1985)
	Valentine, M.A. 264/19 <i>J. Bio. Chem.</i> 11282 (1989)
	Ozato, K. 126/1 <i>J. Immunol.</i> 317 (1981)
	Calvert, J.E. 21/4 <i>Sem. Hema.</i> 226 (1984)
	Anderson, K.C. 63/6 <i>Blood</i> 1424 (1984)
	Oettgen, H.C. 2/1 <i>Hybridoma</i> 17 (1983)
	Lipton, J.M. 60/1 <i>Blood</i> 170a (Abs. 609) (1982)
	Anderson, K.C. 69/2 <i>Blood</i> 597 (1987)
	Adams, R.A. 27/1 <i>Can. Res.</i> 2479 (1967)
	Adams, R.A. 28 <i>Can. Res.</i> 1121 (1968)
12/5	Smeland, E.B. 13810 <i>J. Immunol.</i> 3179 (1987)
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.